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Polymorphisms and antidepressant response 
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Highlights 
 Systematic review on polymorphisms in HPA axis genes and antidepressant response 
 No relationship between SNPs in AVP and AVPR1A and treatment response 
 Equivocal findings in terms of NR3C1, NR3C2, and FKBP5 
 Specific polymorphisms in CRHBP, CRHR1, and POMC predicted non-response 
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Around 50% of depressed patients do not respond to antidepressants. Evidence from familial studies 
suggests a genetic component to this. This study investigated whether patients with polymorphisms in 
genes related to the hypothalamic-pituitary-adrenal (HPA) axis were less likely to respond to 
antidepressants. 
Method 
EMBASE, MEDLINE, PsycINFO, and the Cochrane Library were searched. Inclusionary criteria were: 
1) patients with depression, 2) study of HPA axis-related candidate genes, 3) at least four weeks of 
antidepressants, and 4) assessment of depressive symptoms dividing patients into non-responders 
and responders. 
Results 
Nineteen studies were identified. Non-responders and responders did not differ in single nucleotide 
polymorphisms (SNPs) in genes encoding arginine vasopressin. Findings were equivocal regarding 
genes encoding the FK506 binding protein 5 and glucocorticoid and mineralocorticoid receptors. 
Specific SNPs and haplotypes within genes related to corticotropin-releasing hormone (CRHBP, 
CRHR1) and melanocortins (POMC) predicted non-responder status. 
Conclusions 
Replication studies and additional investigations exploring gene x environment and drug x 
environment interactions are necessary before pharmacological treatments may be adjusted based on 
a patient’s genetic profile. 
Keywords: antidepressant; depression; hypothalamic-pituitary-adrenal axis; polymorphism; treatment 
response  
AC
CE
PT
ED
 M
AN
US
CR
IPT
3 
1. Introduction 
Antidepressants are among the most widely used first-line treatments for patients with depressive 
disorders; however, around 50% of patients are not sufficiently responsive (Cleare et al., 2015). This 
raises the question of the mechanisms underlying the non-response phenomenon. 
Alterations in the stress-responsive hypothalamic-pituitary-adrenal (HPA) axis represent one 
of the most consistent pathophysiological findings in depressive disorders. They include elevated 
levels of corticotropin-releasing hormone (CRH; Waters et al., 2015), elevated levels of 
adrenocorticotropic hormone (ACTH) and cortisol (Stetler and Miller, 2011), reduced glucocorticoid 
sensitivity (Rohleder et al., 2010), and mineralocorticoid to glucocorticoid receptor imbalance (de Kloet 
et al., 2007). As for potential origins of these alterations, candidate-gene association studies have 
shown that polymorphisms in a number of genes related to HPA axis functioning appear to be more 
frequent in some patients with depressive disorders (Cohen-Woods et al., 2013; Ising and Holsboer, 
2006). Among these genes are: AVPR1A, coding for an arginine vasopressin (AVP) receptor; CRH, 
CRHBP, CRHR1 and CRHR2, coding for CRH, its binding protein and its receptors, respectively; 
POMC, involved in the synthesis of proopiomelanocortin, a precursor of ACTH; FKBP5, coding for the 
FK506-binding protein 5, a co-chaperone of glucocorticoid signalling; and NR3C1, a gene coding for 
the glucocorticoid receptor. 
Evidence from meta-analysis suggests that alterations in the HPA axis are related to 
antidepressant treatment response (Fischer et al., 2017a). Higher cortisol concentrations in particular 
appear to be linked with non-responses, although only in studies with a particular methodological 
profile. Given parallel evidence for a familial predisposition towards non-responses to antidepressants 
(Franchini et al., 1998), the aim of the present study was to investigate whether non-responders to 
antidepressant treatment can be distinguished from responders by means of genetic HPA axis 
markers. Based on a previous meta-analysis on single-nucleotide polymorphisms (SNPs) within 
FKBP5 and antidepressant response (Zou et al., 2010) it was hypothesised that non-responders 
would have a higher frequency of specific SNPs and related haplotypes in HPA axis-related genes 
when compared to responders. 
 
2. Method 
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2.1 Search for records 
Relevant records were identified by systematically searching the Cochrane Library, EMBASE, 
MEDLINE, and PsycINFO databases from the first available year until January 2018. Key words and 
exploded subject headings were combined in accordance with the thesaurus of each database. The 
search string consisted of three components: 1) “HPA axis” and synonyms, including relevant genes 
(e.g., “NR3C1”), 2) “depressive disorder”, including synonyms, and 3) “antidepressant” and synonyms, 
including the most widely prescribed antidepressants (e.g., “citalopram”). The search was part of a 
larger systematic search including terms related to anxiety disorders, but these records were not 
considered for the present research question. All searches were restricted to studies conducted in 
humans. Only studies published in English, German, Dutch, French, Italian, or Spanish were to be 
included. 
 
2.2 Screening and study selection 
Identified records were screened according to the following inclusionary criteria: 1) adults with a 
current depressive disorder (i.e., major depressive disorder or persistent depressive disorder) 
diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the 
International Classification of Diseases (ICD), 2) a candidate-gene study of at least one HPA axis-
related gene (i.e., AVP, AVPR1A, AVPR1B, CRH, CRHR1, CRHR2, CRHBP, FKBP5, MC1R, NR3C1, 
NR3C2, POMC), and 3) treatment including at least four weeks of continuous administration of 
antidepressants (i.e., monoamine oxidase (MAO) inhibitors, tri- or tetracyclic antidepressants, 
selective serotonin reuptake inhibitors (SSRIs), noradrenaline reuptake inhibitors, serotonin-
noradrenaline reuptake inhibitors (SNRIs), noradrenaline-dopamine reuptake inhibitors, serotonin-
noradrenalin-dopamine reuptake inhibitors), and 4) including a standardised measure of depressive 
symptoms dividing patients into non-responders and responders or non-remitters and remitters. 
Studies including bipolar patients were excluded. Comorbidity with somatic diseases, other mental 
disorders, intake of any medication upon study entry, and intake of medication pro re nata during the 
study were permitted, but recorded (see risk of bias assessment below). Studies that used more than 
one class of antidepressants were included, but again, this was noted. Full-text articles were retrieved 
and checked for relevant results. All article reference sections were reviewed for additional records of 
potential relevance. 
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2.3 Extraction of study results 
For each retrieved study, information was collected about the sample size, eligibility criteria (e.g., 
medication use), diagnostic procedures, determination of HPA axis-related polymorphisms, blinding, 
antidepressant treatment, response and remission rates, and main findings. Risk of bias was 
estimated by means of a modified version of a quality assessment scale that was used in previous 
meta-analyses on HPA axis functioning as a predictor of treatment response (see Table 1; Fischer 
and Cleare, 2017; Fischer et al., 2017a; Fischer et al., 2017b). Seven items were scored on a three-
point scale (0-2). The maximum attainable score was thus 14. 
 
3. Results 
3.1 Search results 
The search yielded 29,893 records, of which 56 were considered of potential interest based on their 
title or abstract. Of these, 37 were excluded because they were not original research articles (e.g., 
book chapters), were not conducted in adults, included patients with bipolar disorder, were not 
candidate-gene studies of HPA axis-related genes, did not administer antidepressants, administered 
antidepressants for less than four weeks, used augmentation strategies, were retrospective in nature 
(e.g., cross-sectional comparison of genetic HPA axis-related polymorphisms in patients labelled 
“treatment resistant” vs. healthy controls), or did not contain results in terms of either treatment non-
responders versus responders or non-remitters versus remitters. In the end, N=19 studies were 
eligible to be included in the systematic review. 
 
3.2 Study characteristics 
The main characteristics of the 19 included studies are shown in Tables 2-6. All were published 
between 2007 and 2015. The sample sizes ranged from 96 to 1719. Almost all patients fulfilled criteria 
for a major depressive disorder. Virtually no study reported on the prevalence of symptomatic 
subtypes. In total, 84% of studies excluded comorbidity with major mental disorders, 74% excluded 
medication intake at study entry, 53% excluded patients with some degree of previous treatment-
resistance, and 42% excluded patients with major physical diseases. Polymorphisms in HPA axis 
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genes were determined by means of different commercially available assays. Citalopram and 
fluoxetine were the most widely used antidepressants (6 studies each, equalling 64%), followed by 
escitalopram (4 studies, 21%). Antidepressants were administered from 4 to 14 weeks. The average 
response rate across studies was 60%, ranging from 43% to 72% (mostly assessed by the Hamilton 
Rating Scale for Depression; HAMD). The average remission rate was 50%, ranging from 38% to 
69%. 
 
3.3 Risk of bias 
Quality ratings ranged from 2 to 9, with an average of 6 points (14 points maximum). The highest 
scores were achieved regarding the inclusionary and exclusionary criteria, which in general tended to 
be quite restrictive (item 1). Similarly, depressive disorders were diagnosed by clinical psychologists 
and psychiatrists rather than by students in most cases (item 2). Genetic marker selection, population 
stratification, minor allele frequencies and information on the Hardy-Weinberg equilibrium were 
reported by the majority of studies, whereas less than half reported information regarding assay 
reliability or models of penetrance (item 3). Antidepressant dosage was appropriate in more than half 
of the studies (item 4). By contrast, several studies failed to report whether response assessors were 
blind to genotypes (item 6) and statistical analyses were rarely fully adequate (item 7): A power 
analysis was undertaken in only six studies, only five studies controlled for age and sex, four for intake 
of medication pro re nata during treatment, and two for baseline symptom severity. Most studies did, 
however, adjust their results for multiple testing. No study used both clinician-rated and self-reported 
instruments to assess treatment response (item 5). 
 
3.4 Polymorphisms in genes related to the arginine vasopressin (AVP) system 
Three studies looked at polymorphisms in genes related to the AVP system (see Table 1). They were 
conducted in Chinese, Chilean, African American, European American, and Hispanic patients. A 
number of SNPs within AVP, AVPR1A, and AVPR1B were determined and patients were treated with 
different SSRIs and SNRIs for up to 12 weeks. None of the studies found any link between any of 
these SNPs and treatment response or remission. 
 
- Insert Table 1 here - 
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3.5 Polymorphisms in genes related to the corticotropin-releasing hormone (CRH) system 
Nine studies investigated polymorphisms in genes related to the CRH system (see Table 2). Three of 
these focused on CRH. These studies included patients of African American, European American, 
Hispanic, or Mexican American ethnicity. There was no link whatsoever between any SNPs and 
haplotypes located in CRH and response or remission after up to 12 weeks of treatment with tricyclic 
antidepressants, tetracyclic antidepressants, or SSRIs. 
Three studies investigated CRHBP, coding for the CRH binding protein, in relation to 
treatment response. Binder et al. (2010) found that African American and Hispanic patients with a 
particular allele of a SNP in CRHBP (rs10473984) had a nearly two-fold higher probability of being a 
non-responder or non-remitter after up to 12 weeks of treatment with citalopram. 
Six studies focused on CRHR1, coding for one of the CRH receptors. Geng et al. (2014) in 
their sample of Chinese patients found one SNP (rs28364032) and three related haplotypes in CRHR1 
to be associated with an up to seven-fold increased risk of non-remission after 8 weeks of treatment 
with different SSRIs and SNRIs. 
Finally, six studies looked at CRHR2, coding for another CRH receptor. Wong et al. (2008) 
found one SNP in CRHR2 (rs917195) to differ between Mexican American non-responders and 
responders undergoing 8 weeks of treatment with desipramine, while this did not apply to patients 
treated with 8 weeks of fluoxetine. Notably, this result was not adjusted for multiple testing. Tiwari et 
al. (2013) found another SNP in CRHR2 (rs1076292) to differ between African, European, and 
Hispanic non-responders and responders to up to 12 weeks of treatment with bupropion. However, 
this only applied to patients completing treatment and no such association was found with remission 
status. 
 
- Insert Table 2 here - 
 
3.6 Polymorphisms in genes related to the melanocortin system 
Three studies looked at polymorphisms related to the melanocortin system (see Table 3). Two studies 
analysed POMC, coding for a precursor of ACTH. Chang et al. (2015b) found one haplotype 
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comprising four SNPs within POMC to be linked with an up to six-fold increased risk of being a non-
remitter after 8 weeks of treatment with escitalopram or mirtazapine. 
Wu et al. (2011) was the only study investigating polymorphisms in MC1R, coding for one of 
the melanocortin receptors. In their sample of Mexican American patients, two SNPs (rs2228478, 
rs2228479) differed between non-remitters and remitters after 8 weeks of treatment with desipramine, 
but not fluoxetine. However, no correction for multiple testing was applied, rendering this a tentative 
finding. 
 
- Insert Table 3 here - 
 
3.7 Polymorphisms in the gene coding for the FK506 binding protein 5 
Ten studies investigated FKBP5 (see Table 4). In a mixed sample of patients with Black and White 
ethnicities, Lekman et al. (2008) found one SNP (rs4713916) located in FKBP5 to distinguish between 
non-remitters and remitters to up to 14 weeks of treatment with citalopram; it did not, however, 
distinguish non-responders from responders. Ellsworth et al. (2013) failed to replicate this finding in 
patients of White ethnicity undergoing 8 weeks of treatment with citalopram or escitalopram. Similarly, 
Perlis et al. (2009) did not report any significant findings in terms of the same SNP and responder or 
remission status in Caucasian patients who were administered duloxetine over the course of 6 weeks. 
Geng et al. (2014) also did not find any link between the same SNP and response to 8 weeks of 
treatment with different SSRIs and SNRIs in their Chinese sample. 
 
- Insert Table 4 here - 
 
3.8 Polymorphisms in genes coding for the glucocorticoid and mineralocorticoid receptor 
Nine studies investigated polymorphisms related to the glucocorticoid and mineralocorticoid receptor 
(see Table 5). Eight studies sequenced NR3C1, coding for the glucocorticoid receptor. In their study of 
Japanese patients, Takahashi et al. (2014) found one SNP (rs41423247) in NR3C1 to differ between 
non-responders and responders to 6 weeks of fluvoxamine treatment, while it failed to differ between 
non-remitters and remitters. No differences whatsoever were found for the subgroup of their patients 
undergoing 6 weeks of milnacipran treatment. Geng et al. (2014) did not find the same SNP to 
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distinguish between Chinese non-responders and responders to 8 weeks of SSRI or SNRI treatment. 
Similarly, Ventura-Junca et al. (2014) could not replicate the positive finding in their Chilean sample 
undergoing 8 weeks of fluoxetine treatment, and neither could Lee et al. (2009) in a Korean sample of 
patients who were treated with citalopram for 8 weeks. 
Paddock et al. (2007) was the only study to sequence NR3C2, coding for the mineralocorticoid 
receptor. This was a sample of patients with Black or White ethnicity and no significant associations 
between SNPs in NR3C2 and responder or remitter status after 6 weeks of administering citalopram 
were reported. 
 
- Insert Table 5 here - 
 
4. Discussion 
The systematic review yielded three main findings (see also Table 6 for a summary). First, genes 
coding for the CRH and melanocortin systems appear to contain a number of SNPs and haplotypes, 
which are able to predict antidepressant response in depressed patients. Second, findings related to 
genes coding for FKBP5 and the glucocorticoid and mineralocorticoid receptors are equivocal. Finally, 
there was a considerable risk of bias, which was mainly due to missing detail on how candidate-gene 
studies were conducted, a lack of a priori power analyses and statistical adjustment for relevant 
confounders, and failure to report blinding procedures. 
 
- Insert Table 6 here - 
 
The first finding of this systematic review is that SNPs and haplotypes within CRHBP, CRHR1, 
and POMC have emerged as particularly powerful predictors of antidepressant response. Binder et al. 
(2010) found a specific SNP (rs10473984) located in CRHBP to distinguish between non-responders 
and responders to citalopram. This finding was most recently extended by O'Connell et al. (2018), who 
found another SNP (rs28365143) within CRHBP to predict responses to escitalopram and sertraline. 
Importantly, in the Binder et al. study, the same allele predicting non-response was also linked with 
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greater serum ACTH concentrations. In addition, Geng et al. (2014) found a SNP (rs28364032) and 
related haplotypes within CRHR1 to predict remission after administering various SSRIs and SNRIs, 
and Chang et al. (2015b) found a haplotype within POMC to predict remission status after treatment 
with escitalopram or mirtazapine. Notably, studies reporting positive findings in terms of the CRH and 
melanocortin system had a much higher average quality score (7.3 out of 14) when compared to those 
reporting null-findings (4.5 out of 14), which highlights the need for further research adhering to high 
standards. When taken together, these findings resonate well with evidence of enhanced CRH 
(Waters et al., 2015) and ACTH (Stetler and Miller, 2011) levels in patients with depressive disorders; 
however, not all functional links between these SNPs and HPA axis parameters have yet been 
established. Evidence for causative effects of these polymorphisms is warranted to increase our 
knowledge on how exactly genetic variance may affect antidepressant treatment.  
The second finding of this systematic review purports that although pharmacogenetic studies 
focusing on FKBP5 and NR3C1 are manifold, results are far from conclusive. In terms of FKBP5, 
Lekman et al. (2008) found a particular SNP (rs4713916) to predict remission status after 
administering citalopram. This aligns well with the fact that the same SNP resides within a functional 
region of FKBP5, implying causative links with FKBP5 protein expression (Zou et al., 2010). However, 
three more recent studies included in the present systematic review were unable to replicate this 
finding (Ellsworth et al., 2013; Geng et al., 2014; Perlis et al., 2009). While two of these studies (Geng 
et al., 2014; Perlis et al., 2009) used SNRIs and are thus not directly comparable to the Lekman et al. 
study, Ellsworth et al. (2013) also administered citalopram and escitalopram. According to the authors, 
divergent sample characteristics are likely to account for the observed discrepancy. One obvious 
difference is ethnicity, which in the Lekman et al. study was mixed (Black and White non-Hispanic) 
whereas Ellsworth et al.’s sample was restricted to individuals of White non-Hispanic ethnicity. Equally 
conflicting findings were revealed regarding NR3C1. Takahashi et al. (2014) found that the Bcl1 
polymorphism (rs41423247) separated Japanese non-responders and responders when they received 
fluvoxamine, while there was no apparent effect on response rates when patients received 
milnacipran. Three studies investigating the same SNP were unable to replicate this finding (Geng et 
al., 2014; Lee et al., 2009; Ventura-Junca et al., 2014) and again, ethnic diversity is a likely candidate 
in explaining these inconsistent findings. Further attempts at replicating the positive findings by 
Lekman et al. (2008) and Takahashi et al. (2014) in ethnically homogenous samples are thus 
imperative. 
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Should the above findings be replicated, it is conceivable for depressed patients with a 
specific, HPA axis-related genetic predisposition to be less likely to respond to first-line treatments, 
such as antidepressants. The most likely mechanism translating these variants into non-responses is 
via measurable alterations in the HPA axis. Indeed, some studies have been successful in linking pre-
treatment cortisol concentrations with antidepressant response (Fischer et al., 2017a). In addition, 
antidepressants have repeatedly been demonstrated to normalise HPA axis functioning (Holsboer, 
2000), presumably via modulating glucocorticoid receptor functioning (Anacker et al., 2011). In 
addition, interactions of the HPA axis with other stress-responsive systems, such as the immune 
system, may modulate treatment response (Strawbridge et al., 2015), and a more comprehensive 
account of pre-treatment alterations in stress-responsive bodily systems may thus be necessary to 
understand the mechanisms contributing to non-responses. However, this would imply a functional 
role of these polymorphisms in HPA axis functioning, and evidence for this remains outstanding for 
several of the SNPs identified in this systematic review. 
Importantly, the genetic variance within HPA axis-related genes is unlikely to exert its potential 
influence on treatment response in isolation. Instead, there is a high probability for gene-environment 
interactions to occur. Some of the included studies have considered this by stratifying patients 
according to the presence of stressful life events (Chang et al., 2015a; Chang et al., 2015b; Geng et 
al., 2014). Indeed, Chang et al.’s (2015b) finding of a haplotype within POMC to predict non-remission 
was mainly driven by the subgroup of patients not reporting any stressful life events within the year 
preceding the current major depressive episode. This aligns well with more recent efforts exploring 
epigenetic modifications as predictors and modulators of treatment response (Belzeaux et al., 2018). 
In contrast, Geng et al. (2014) found neither childhood trauma nor stressful life events within the past 
year to interact with a specific SNP within CRHR1 to predict remitter status. Further studies may be 
well-advised to include detailed histories of stressful experiences across the lifespan, and to 
complement genetic with epigenetic markers of the HPA axis. Related to this, drug-environment 
interactions should be considered by future research. This is important given that recent data suggest 
that the effect of antidepressants and psychoactive substances in general are co-determined by 
environmental factors, such as socioeconomic status or pre-treatment psychological state (Carhart-
Harris et al., 2018; Chiarotti et al., 2017). 
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This is the first systematic review of HPA axis-related polymorphisms and antidepressant 
treatment response. Strengths of this study include the comprehensive literature search, the fact that 
we defined a distinct phenotype in terms of treatment response (non-responder vs. responder status), 
and our rigorous risk of bias assessment. On the other hand, relatively few studies matching our 
eligibility criteria were identified and a number of methodological issues became apparent during the 
risk of bias assessment. More specifically, the reporting of SNP assay performance and penetrance 
models, the use of an adequate dosage of antidepressants, the conducting of an a priori power 
analysis and adjustment for important confounders was insufficient in several of the included studies. 
This points to potential reasons for some of the null-findings as reported above, and it is thus strongly 
recommended that future studies are more vigilant in terms of these issues. Finally, due to the 
heterogeneity of the included studies it was not possible to integrate findings in a quantitative manner. 
Further research investigating the same SNPs and haplotypes identified in this review is warranted 
before a meaningful meta-analysis can be undertaken. 
In sum, this systematic review has identified a number of HPA axis-related SNPs that hold the 
promise of identifying non-responders to antidepressant treatments. The current state of the literature 
suggests that these are primarily located within genes coding for the CRH and melanocortin systems, 
while the role of polymorphisms within FKBP5 and NR3C1 remains ambiguous. Further large-scale 
studies including additional HPA axis markers (e.g., DNA methylation, gene expression) and stratifying 
patients according to their current and past levels of stress and other environmental factors are 
necessary before additional or alternative treatments should be preferentially considered based on a 
patient’s genetic profile.  
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Table 1 Characteristics of identified studies on polymorphisms in genes related to the arginine 
vasopressin (AVP) system and response to antidepressant treatment 
Table 2 Characteristics of identified studies on polymorphisms in genes related to the corticotropin-
releasing hormone (CRH) system and response to antidepressant treatment; all positive findings 
adjusted for multiple testing unless stated otherwise 
Table 3 Characteristics of identified studies on polymorphisms in genes related to the melanocortin 
system and response to antidepressant treatment; all positive findings adjusted for multiple testing 
unless stated otherwise 
Table 4 Characteristics of identified studies on polymorphisms in the FK506 binding protein 5 (FKBP5) 
gene and response to antidepressant treatment; all positive findings adjusted for multiple testing 
unless stated otherwise 
Table 5 Characteristics of the identified studies on polymorphisms in genes related to the 
mineralocorticoid and glucocorticoid receptors and response to antidepressant treatment; all positive 
findings adjusted for multiple testing unless stated otherwise 
Table 6 Summary of findings divided by whether they are supportive or non-supportive of a 
relationship between polymorphisms in genes related to the hypothalamic-pituitary-adrenal axis and 
response to antidepressant treatment; note that different single nucleotide polymorphisms and 
haplotypes were investigated across studies (see results section for more details) 
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Table 1 Characteristics of identified studies on polymorphisms in genes related to the arginine vasopressin (AVP) system and response to antidepressant 
treatment 
Study Sample Diagnosis Gene Treatment Response/ 
remission rate 
Main findings Quality 
rating 
Geng, 2014 N=273 
n=164 female 
n=109 male 
Age: 39±13 years 
Ethnicity: Chinese 
Inclusion: HAMD-17 
≥18 
Exclusion: history of 
substance abuse, 
schizophrenia, 
schizoaffective 
disorder, bipolar 
disorder, generalised 
anxiety disorder, panic 
disorder, obsessive-
compulsive disorder, 
personality disorder, 
mental retardation, 
primary organic 
Diagnosis: 
Psychiatric 
evaluation 
Subtype: 
Not stated 
AVPR1A 
SNaPshot 
Multiplex Kit 
Different types 
of SSRIs and 
SNRIs 
Dosage: Not 
stated 
8 weeks 
55% remitters 
(HAMD-17 7) 
No association between 
SNPs in AVPR1A and 
remission 
8/14 
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diseases, pregnancy, 
lactation, drugs within 
2 weeks, 
electroconvulsive 
therapy within 6 
months 
Ventura-Junca, 
2014 
N=208 
n=201 female 
n=7 male 
Age: 43±11 years 
Ethnicity: Chilean 
Inclusion: HAMD-17 
≥15 
Exclusion: substance 
abuse, psychotic 
disorder, bipolar 
disorder, generalised 
anxiety disorder, panic 
disorder, obsessive-
compulsive disorder, 
severe cognitive 
impairment, 
medical/neurological 
illness, acute/chronic 
infections, abnormal 
thyroid function, 
hypertension, 
Diagnosis: 
MINI 
Subtype: 
Not stated 
AVP 
Restriction 
fragment 
length 
polymorphism 
strategy 
Fluoxetine 
20mg/day 
(weeks 1-3), 
increasing to 
40mg/day 
(flexible, 
depending on 
tolerance) 
8 weeks 
55% responders 
(50% reduction 
HAMD-17) 
39% remitters 
(HAMD-17 ≤7) 
No association between 
SNPs in AVP and 
treatment response or 
remission 
7/14 
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pregnancy, 
breastfeeding, 
medication within 2 
months prior to study, 
history of treatment-
resistant MDD 
Binder, 2010 N=1719 
Sex: Not stated 
Age: 18-75 years 
Ethnicity: African 
American, European 
American, Hispanic 
Inclusion: HAMD ≥14 
and QIDS-C ≥10 
Exclusion: psychotic 
disorder, bipolar 
disorder, obsessive 
compulsive disorder, 
primary eating 
disorder, pregnant or 
breastfeeding, intake of 
citalopram, treatment 
resistance 
Diagnosis: 
Clinician 
based 
Subtype: All 
non-
psychotic 
AVP, 
AVPR1A, 
AVPR1B 
SNPlex 
System 
Citalopram 
20mg/day 
(weeks 1-3), 
increasing to 
40mg/day 
(week 4) and 
60mg/day 
(week 6) 
4-12 weeks 
57% responders 
(50% reduction 
QIDS-C) 
43% remitters 
(QIDS-C 5), 
38% non-
remitters (QIDS-C 
≥10) 
No association between 
SNPs in AVP, AVPR1A, 
AVPR1B, and treatment 
response or remission 
8/14 
AVP = arginine vasopressin, AVPR = arginine vasopressin receptor, HAMD = Hamilton Rating Scale for Depression, MINI = Mini International Neuropsychiatric 
Interview, QIDS-C = Quick Inventory of Depressive Symptomatology – Clinician-Rated, SCID = Structured Clinical Interview for DSM, SNRI = selective 
noradrenaline reuptake inhibitors, SSRIs = selective serotonin reuptake inhibitors 
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Table 2 Characteristics of identified studies on polymorphisms in genes related to the corticotropin-releasing hormone (CRH) system and response to 
antidepressant treatment; all positive findings adjusted for multiple testing unless stated otherwise 
Study Sample Diagnosis Gene Treatment Response/ 
remission rate 
Main findings Quality 
rating 
Chang, 2015a N=149 
n=118 female 
n=31 male 
Age: 51±16 years 
Ethnicity: unclear 
Inclusion: HAMD-21 
≥18 
Exclusion: 
substance 
dependence, 
schizophrenia, 
schizoaffective 
disorder, bipolar 
disorder, dementia, 
serious or unstable 
medical illness, 
psychotropic 
Diagnosis: 
SCID 
Subtype: 
Not stated 
CRH 
SNaPshot 
Multiplex Kit 
Escitalopram 
(5-40mg) 
Mirtazapine 
(15-30mg) 
12 weeks 
41% remitters 
(HAMD-21 ≤7) 
No association between 
SNPs or haplotypes in CRH 
and remission 
6/14 
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medication within 2 
weeks 
Geng, 2014 N=273 
n=164 female 
n=109 male 
Age: 39±13 years 
Ethnicity: Chinese 
Inclusion: HAMD-17 
≥18 
Exclusion: history of 
substance abuse, 
schizophrenia, 
schizoaffective 
disorder, bipolar 
disorder, 
generalised anxiety 
disorder, panic 
disorder, obsessive-
compulsive 
disorder, personality 
disorder, mental 
retardation, primary 
organic diseases, 
pregnancy, 
lactation, drugs 
within 2 weeks, 
electroconvulsive 
Diagnosis: 
Psychiatric 
evaluation 
Subtype: 
Not stated 
CRHR1, 
CRHR2 
SNaPshot 
Multiplex Kit 
Different types 
of SSRIs and 
SNRIs 
Dosage: Not 
stated 
8 weeks 
55% remitters 
(HAMD-17 7) 
One SNP (rs28364032) and 
three haplotypes in CRHR1 
differed between non-
remitters and remitters 
No association between 
SNPs in CRHR2 and 
remission 
8/14 
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therapy within 6 
months 
Ventura-Junca, 
2014 
N=208 
n=201 female 
n=7 male 
Age: 43±11 years 
Ethnicity: Chilean 
Inclusion: HAMD-17 
≥15 
Exclusion: 
substance abuse, 
psychotic disorder, 
bipolar disorder, 
generalised anxiety 
disorder, panic 
disorder, obsessive-
compulsive 
disorder, sever 
cognitive 
impairment, 
medical/neurological 
illness, 
acute/chronic 
infections, abnormal 
thyroid function, 
hypertension, 
pregnancy, 
Diagnosis: 
MINI 
Subtype: 
Not stated 
CRHR1, 
CRHR2 
Restriction 
fragment length 
polymorphism 
strategy 
Fluoxetine 
20mg (weeks 
1-3), increasing 
to 40mg 
(flexible, 
depending on 
tolerance) 
8 weeks 
55% responders 
(50% reduction 
HAMD-17) 
39% remitters 
(HAMD-17 ≤7) 
No association between 
SNPs in CRHR1 or CRHR2 
and treatment response or 
remission 
7/14 
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breastfeeding, 
medication within 2 
months prior to 
study, history of 
treatment-resistant 
MDD 
Tiwari, 2013 N=319 
n=199 female 
n=120 male 
Age: 39±12 years 
Ethnicity: African, 
European, Mexican 
Inclusion: HAMD-17 
≥17 or IDS-C ≥25 
Exclusion: alcohol 
or substance abuse, 
schizophrenia, 
bipolar disorder, 
panic disorder, 
obsessive-
compulsive 
disorder, post-
traumatic stress 
disorder, acute 
stress disorder, 
eating disorder, 
seizure disorder, 
Diagnosis: 
Investigator 
evaluation 
Subtype: 
Not stated 
CRHR2 
iPLEX Platform 
Bupropion 
(150-450mg) 
4-12 weeks 
60% responders 
(50% reduction 
HAMD-17 or 
IDS-C) 
42% remitters 
(HAMD-17 ≤7 or 
IDS-C ≤13) 
Only in treatment completers 
did non-responders and 
responders differ in a SNP 
(rs1076292) in CRHR2 
No association between 
SNPs in CRHR2 and 
remission 
4/14 
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brain injury, 
unstable medical 
condition, 
psychotropic drugs 
within 2 weeks 
Binder, 2010 N=1719 
Sex: Not stated 
Age: 18-75 years 
Ethnicity: African 
American, European 
American, Hispanic 
Inclusion: HAMD 
≥14 and QIDS-C 
≥10 
Exclusion: psychotic 
disorder, bipolar 
disorder, obsessive 
compulsive 
disorder, primary 
eating disorder, 
pregnant or 
breastfeeding, 
intake of citalopram, 
treatment resistance 
Diagnosis: 
Clinician 
based 
Subtype: All 
non-
psychotic 
CRH, CRHBP, 
CRHR1, 
CRHR2 
SNPlex 
System, 
TaqMan Assay 
Citalopram 
20mg (weeks 
1-3), increasing 
to 40mg (week 
4) and 60mg 
(week 6) 
4-12 weeks 
57% responders 
(50% reduction 
QIDS-C) 
43% remitters 
(QIDS-C 5), 
38% non-
remitters (QIDS-
C ≥10) 
One SNP (rs10473984) in 
CRHBP differed between 
African American non-
responders and responders, 
and between Hispanic non-
responders and responders 
(additive model only for the 
latter ethnicity) 
The same SNP differed 
between African Americans 
and Hispanic non-remitters 
and remitters 
No association between 
SNPs in CRH, CRHR1, 
CRHR2 and treatment 
response or remission 
8/14 
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Dong, 2009 N=272 
n=180 female 
n=92 male 
Age: 38±10 years 
Ethnicity: Mexican 
American 
Inclusion: HAMD-21 
≥18 and depressed 
mood item ≥2 
Exclusion: any other 
mental disorder, 
suicidal ideation, 
pregnancy, 
lactation, current 
use of medication 
interfering with 
electro-
encephalography, 
antidepressant 
intake within 2 
weeks, drug use or 
alcohol abuse within 
3 months, enrolment 
in psychotherapy, 
treatment resistance 
Diagnosis: 
SCID 
Subtype: 
Not stated 
CRHR1 
Sequencing 
(Big DyeTM) 
Desipramine 
(50-200mg) 
Fluoxetine (10-
40mg) 
8 weeks 
Remission rate: 
not stated 
(HAMD-21 <8) 
No association between 
SNPs in CRHR1 and 
remission 
5/14 
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Wong, 2008 N=230 
n=154 female 
n=76 male 
Age: 21-68 years 
Ethnicity: Mexican 
American 
Inclusion: HAMD-21 
≥18 and depressed 
mood item ≥2 
Exclusion: any other 
mental disorder 
except anxiety 
disorders, suicidal 
ideation, pregnancy, 
lactation, current 
use of medication 
interfering with 
electro-
encephalography, 
antidepressant 
intake within 2 
weeks, drug use or 
alcohol abuse within 
3 months, enrolment 
in psychotherapy, 
treatment resistance 
Diagnosis: 
Unclear 
Subtype: 
Not stated 
CRH, CRHBP, 
CRHR2 
Golden Gate 
Assay 
Desipramine 
(50-200mg) 
Fluoxetine (10-
40mg) 
8 weeks 
Responder rate: 
not stated (50% 
reduction HAMD-
21) 
One SNP in CRHR2 
(rs917195) differed between 
non-responders and 
responders to desipramine 
(unadjusted for multiple 
testing) 
No association between 
SNPs in CRH or CRHBP 
and treatment response 
2/14 
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Liu, 2007 N=127 
n=72 female 
n=55 male 
Age: 31±11 years 
Ethnicity: Chinese 
Inclusion: HAMD-21 
≥18 
Exclusion: recent 
suicide attempt, 
substance abuse, 
schizophrenia, 
bipolar disorder, 
generalised anxiety 
disorder, panic 
disorder, obsessive 
compulsive 
disorder, personality 
disorder, pregnancy, 
major 
medical/neurological 
disorder, intake of 
antidepressants 
within 2 weeks, 
electroconvulsive 
therapy within 6 
months, current 
psychotherapy, 
Diagnosis: 
Psychiatric 
evaluation 
Subtype: 
Not stated 
CRHR1 
TaqMan Assay 
Fluoxetine 
20mg (weeks 
1-2), up to 
40mg 
6 weeks 
53% responders 
(50% reduction 
HAMD-21) 
No association between 
SNPs in CRHR1 and 
treatment response 
8/14 
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previous lack of 
response to 
fluoxetine 
Papiol, 2007 N=159 
n=124 female 
n=35 male 
Age:40±12 years 
Ethnicity: unclear 
Inclusion: No criteria 
Exclusion: bipolar 
disorder, 
antidepressants 
within 2 weeks 
Diagnosis: 
SCID 
Subtype: 
unclear 
CHRBP, 
CRHR1, 
CRHR2 
SNaPshot 
Multiplex Kit 
Citalopram (20-
40mg) 
4 weeks 
(response), 12 
weeks 
(remission) 
65% responders 
(50% reduction 
HAMD-21) 
69% remitters 
(HAMD-21 ≤7) 
No association between 
SNPs in CRHR2 and 
treatment response 
4/14 
CRH = corticotropin releasing hormone, CRHR = corticotropin releasing hormone receptor, CRHRBP = corticotropin releasing hormone binding protein, HAMD = 
Hamilton Rating Scale for Depression, IDS-C = Inventory of Depressive Symptoms – Clinician-Rated, QIDS-C = Quick Inventory of Depressive Symptomatology 
– Clinician-Rated, SCID = Structured Clinical Interview for DSM, SNRI = selective noradrenaline reuptake inhibitors, SSRIs = selective serotonin reuptake 
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Table 3 Characteristics of identified studies on polymorphisms in genes related to the melanocortin system and response to antidepressant treatment; all positive 
findings adjusted for multiple testing unless stated otherwise 
Study Sample Diagnosis Gene Treatment Response/ 
remission rate 
Main findings Quality 
rating 
Chang, 2015b N=145 
n=114 female 
n=31 male 
Age: 51±16 years 
Ethnicity: unclear 
Inclusion: HAMD-
21 ≥18 
Exclusion: 
schizophrenia, 
schizoaffective 
disorder, bipolar 
disorder, 
dementia, serious 
or unstable 
medical illness, 
substance abuse 
within 6 months, 
psychotropic drug 
Diagnosis: 
SCID 
Subtype: Not 
stated 
POMC 
SNaPshot 
Multiplex Kit 
Escitalopram 
(5-40mg) 
Mirtazapine 
(15-30mg) 
8 weeks 
38% remitters 
(HAMD-21 7) 
One haplotype in POMC 
differed between non-
remitters and remitters 
(recessive and co-dominant 
models) 
6/14 
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intake within 2 
weeks 
Wu, 2011 N=181 
Sex: Not stated 
Age: 21-68 years 
Ethnicity: 
Mexican 
American 
Inclusion: HAMD-
21 ≥18 and 
depressed mood 
item ≥2 
Exclusion: any 
other mental 
disorder except 
anxiety disorders, 
suicidal ideation, 
pregnancy, 
lactation, current 
use of medication 
interfering with 
electro-
encephalography, 
antidepressant 
intake within 2 
weeks, drug use 
or alcohol abuse 
within 3 months, 
Diagnosis: 
Unclear 
Subtype: Not 
stated 
MC1R 
BigDye 
Terminator v3.1 
Sequencing Kit 
Desipramine 
(50-200mg) 
Fluoxetine (10-
40mg) 
8 weeks 
61% remitters 
(HAMD-21 <8) 
Two SNPs (rs2228479, 
rs2228478) in MC1R differed 
between desipramine non-
responders and responders 
(unadjusted for multiple 
testing) 
2/14 
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enrolment in 
psychotherapy, 
treatment 
resistance 
Wong, 2008 N=230 
n=154 female 
n=76 male 
Age: 21-68 years 
Ethnicity: 
Mexican 
American 
Inclusion: HAMD-
21 ≥18 and 
depressed mood 
item ≥2 
Exclusion: any 
other mental 
disorder except 
anxiety disorders, 
suicidal ideation, 
pregnancy, 
lactation, current 
use of medication 
interfering with 
electro-
encephalography, 
antidepressant 
Diagnosis: 
Unclear 
Subtype: Not 
stated 
POMC 
Golden Gate 
Assay 
Desipramine 
(50-200mg) 
Fluoxetine (10-
40mg) 
8 weeks 
Responder rate: 
not stated (50% 
reduction 
HAMD-21) 
No association between 
SNPs in POMC and 
treatment response 
2/14 
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intake within 2 
weeks, drug use 
or alcohol abuse 
within 3 months, 
enrolment in 
psychotherapy, 
treatment 
resistance 
HAMD = Hamilton Rating Scale for Depression, MC1R = melanocortin receptor, POMC = proopiomelanocortin, SCID = Structured Clinical Interview for DSM 
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Table 4 Characteristics of identified studies on polymorphisms in the FK506 binding protein 5 (FKBP5) gene and response to antidepressant treatment; all 
positive findings adjusted for multiple testing unless stated otherwise 
Study Sample Diagnosis Gene Treatment Response/ 
remission rate 
Main findings Quality 
rating 
Geng, 2014 N=273 
n=164 female 
n=109 male 
Age: 39±13 years 
Ethnicity: Chinese 
Inclusion: HAMD-17 
≥18 
Exclusion: history of 
substance abuse, 
schizophrenia, 
schizoaffective disorder, 
bipolar disorder, 
generalised anxiety 
disorder, panic disorder, 
obsessive-compulsive 
disorder, personality 
disorder, mental 
retardation, primary 
organic diseases, 
Diagnosis: 
Psychiatric 
evaluation 
Subtype: 
Not stated 
FKBP5 
Multiplex 
SNaPshot 
System 
Different types of 
SSRIs and SNRIs 
Dosage: Not 
stated 
8 weeks 
55% remitters 
(HAMD-17 7) 
No association between 
SNPs in FKBP5 and 
remission 
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pregnancy, lactation, 
drugs within 2 weeks, 
electroconvulsive 
therapy within 6 months 
Ventura-Junca, 
2014 
N=208 
n=201 female 
n=7 male 
Age: 43±11 years 
Ethnicity: Chilean 
Inclusion: HAMD-17 
≥15 
Exclusion: substance 
abuse, psychotic 
disorder, bipolar 
disorder, generalised 
anxiety disorder, panic 
disorder, obsessive-
compulsive disorder, 
sever cognitive 
impairment, 
medical/neurological 
illness, acute/chronic 
infections, abnormal 
thyroid function, 
hypertension, 
pregnancy, 
breastfeeding, 
Diagnosis: 
MINI 
Subtype: 
Not stated 
FKBP5 
Restriction 
fragment 
length 
polymorphism 
strategy 
Fluoxetine 
20mg (weeks 1-3), 
increasing to 
40mg (flexible, 
depending on 
tolerance) 
8 weeks 
55% 
responders 
(50% reduction 
HAMD-17) 
39% remitters 
(HAMD-17 ≤7) 
No association between 
SNPs in FKBP5 and 
treatment response or 
remission 
7/14 
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medication within 2 
months prior to study, 
history of treatment-
resistant MDD 
Ellsworth, 2013 N=512 
Sex: Not stated 
Age: Not stated 
Ethnicity: White non-
Hispanic 
Inclusion: HAMD ≥14 
Exclusion: bipolar 
disorder 
Diagnosis: 
Not stated 
Subtype: All 
non-
psychotic 
FKBP5 
BeadXpress 
System 
Citalopram (20mg, 
up to 40mg at 
week 4) 
Escitalopram 
(10mg, up to 
20mg at week 4) 
8 weeks 
Responder 
rate: not stated 
(50% reduction 
QIDS-C) 
Remitter rate: 
not stated 
(QIDS-C ≤5) 
No association between 
SNPs in FKBP5 and 
treatment response or 
remission 
4/14 
Tiwari, 2013 N=319 
n=199 female 
n=120 male 
Age: 39±12 years 
Ethnicity: African, 
European, Mexican 
Inclusion: HAMD-17 
≥17 or IDS-C ≥25 
Diagnosis: 
Investigator 
evaluation 
Subtype: 
Not stated 
FKBP5 
iPLEX Platform 
Bupropion (150-
450mg) 
4-12 weeks 
60% 
responders 
(50% reduction 
HAMD-17 or 
IDS-C) 
42% remitters 
(HAMD-17 ≤7 
or IDS-C ≤13) 
No association between 
SNPs in FKBP5 and 
treatment response or 
remission 
4/14 
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Exclusion: alcohol or 
substance abuse, 
schizophrenia, bipolar 
disorder, panic disorder, 
obsessive-compulsive 
disorder, post-traumatic 
stress disorder, acute 
stress disorder, eating 
disorder, seizure 
disorder, brain injury, 
unstable medical 
condition, psychotropic 
drugs within 2 weeks 
Perlis, 2009 N=250 
n=158 female 
n=92 male 
Age: 44±13 years 
Ethnicity: Caucasian 
Inclusion: HAMD-17 
≥15 
Exclusion: current 
mental disorder except 
dysthymia or anxiety 
disorders, history of 
psychosis, bipolar 
disorder, suicidal risk, 
Diagnosis: 
MINI 
Subtype: 
Not stated 
FKBP5 
iPlex Platform 
Duloxetine 
30-60mg (week 1), 
60mg (weeks 2-6) 
6 weeks 
51% responder 
(50% reduction 
HAMD-17) 
44% remitter 
(HAMD-17 ≤7) 
No association between 
SNPs in FKBP5 and 
treatment response or 
remission 
6/14 
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serious medical illness, 
electroconvulsive 
therapy within 12 
months, treatment with 
MAO inhibitors within 2 
weeks, fluoxetine within 
4 weeks, substance 
abuse within 6 months, 
change in 
psychotherapy, 
treatment resistant 
depression, lack of 
response to duloxetine 
Uher, 2009 N=811 
n=514 female 
n=297 male 
Age: 43±12 years 
Ethnicity: European 
Inclusion: major 
depressive episode of 
at least moderate 
severity 
Exclusion: substance 
abuse, family history of 
bipolar disorder or 
schizophrenia, history 
of (hypo)manic episode, 
Diagnosis: 
SCAN 
Subtype: 
Not stated 
FKBP5 
SNPlex 
System 
Escitalopram 
(10mg increasing 
to 15mg by week 
2, with further 
increasing up to 
30mg) 
Nortriptyline 
(50mg increasing 
to 100mg by week 
2, with further 
increasing up to 
200mg) 
12 weeks 
Responder 
rate: not stated 
(50% reduction 
HAMD-17) 
No association between 
SNPs in FKBP5 and 
treatment response or 
remission 
5/14 
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schizophrenia, mood 
incongruent psychotic 
symptoms, primary 
organic disease, 
pregnancy, MAO 
inhibitors or fluoxetine 
within 2 weeks, history 
of non-response to 
study medication 
Lekman, 2008 N=1370 
Sex: Not stated 
Age: 18-75 years 
Ethnicity: Black, White 
Hispanic, White non-
Hispanic, Other 
Inclusion: HAMD-17 
≥14 and QIDS-C ≥10 
Exclusion: bipolar 
disorder, schizophrenia, 
schizoaffective disorder, 
current obsessive 
compulsive disorder, 
primary eating disorder, 
pregnancy, intake of 
citalopram within 7 
days, treatment 
resistance 
Diagnosis: 
Clinician 
based 
Subtype: All 
non-
psychotic 
FKBP5 
TaqMan Assay 
Citalopram 
Dosage: Not 
stated 
6 to 14 weeks 
70% 
responders 
(50% reduction 
QIDS-C), 30% 
non-
responders 
(<40% 
reduction 
QIDS-C) 
53% remitters 
(QIDS-C ≤5), 
34% non-
remitters 
(QIDS-C ≥10) 
One SNP (rs4713916) in 
FKBP5 differed between 
non-remitters and 
remitters 
No association between 
SNPs in FKBP5 and 
treatment response 
7/14 
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Paddock, 2007 N=935 
Sex: Not stated 
Age: 18-75 years 
Ethnicity: Black, White 
Non-Hispanic 
Inclusion: HAM-D ≥14 
and QIDS-C ≥10 
Exclusion: primary 
diagnosis of bipolar, 
psychotic, obsessive-
compulsive or eating 
disorder, pregnancy, 
breastfeeding, history of 
nonresponse to 
citalopram 
Diagnosis: 
Clinician 
based 
Subtype: All 
non-
psychotic 
FKBP5 
BeadArray 
Platform 
Citalopram 
20mg (weeks 1-3), 
increasing to 
40mg (week 4) 
and 60mg (week 
6) 
6 weeks 
72% 
responders 
(50% reduction 
QIDS-C), non-
responder rate: 
28% (≤40% 
reduction 
QIDS-C) 
Remitter rate: 
not stated 
(QIDS-C ≤5), 
non-remitter 
rate: not stated 
(QIDS-C ≥10) 
No association between 
SNPs in FKBP5 and 
treatment response or 
remission 
7/14 
Papiol, 2007 N=159 
n=124 female 
n=35 male 
Age:40±12 years 
Ethnicity: unclear 
Inclusion: No criteria 
Diagnosis: 
SCID 
Subtype: 
unclear 
FKBP5 
TaqMan Assay 
Citalopram (20-
40mg) 
4 weeks 
(response), 12 
weeks (remission) 
65% 
responders 
(50% reduction 
HAMD-21) 
69% remitters 
(HAMD-21 ≤7) 
No association between 
SNPs in FKBP5 and 
treatment response or 
remission 
4/14 
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Exclusion: bipolar 
disorder, 
antidepressants within 2 
weeks 
Tsai, 2007 N=125 
n=69 female 
n=56 male 
Age: 42±16 years 
Ethnicity: Chinese 
Inclusion: HAMD-21 
≥18 
Exclusion: substance 
abuse, schizophrenia, 
bipolar disorder, 
generalised anxiety 
disorder, panic disorder, 
obsessive-compulsive 
disorder, major 
medical/neurological 
disorder, 
antidepressants within 2 
weeks 
Diagnosis: 
Psychiatric 
evaluation 
Subtype: 
Not stated 
FKBP5 
Restriction 
enzyme 
Fluoxetine (20mg) 
4 weeks 
43% 
responders 
(50% reduction 
HAMD-21) 
No association between 
SNP in FKBP5 and 
treatment response or 
remission 
9/14 
FKBP = FK506 binding protein, HAMD = Hamilton Rating Scale for Depression, MAO = monoamine oxidase inhibitor, MINI = Mini-International Neuropsychiatric 
Interview, QIDS-C = Quick Inventory of Depressive Symptomatology – Clinician-Rated, SNRI = selective noradrenaline reuptake inhibitors, SSRIs = selective 
serotonin reuptake inhibitors 
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Table 5 Characteristics of the identified studies on polymorphisms in genes related to the mineralocorticoid and glucocorticoid receptors and response to 
antidepressant treatment; all positive findings adjusted for multiple testing unless stated otherwise 
Study Sample Diagnosis Gene Treatment Response/ 
remission rate 
Main findings Quality 
rating 
Geng, 2014 N=273 
n=164 female 
n=109 male 
Age: 39±13 years 
Ethnicity: Chinese 
Inclusion: HAMD-17 
≥18 
Exclusion: history of 
substance abuse, 
schizophrenia, 
schizoaffective disorder, 
bipolar disorder, 
generalised anxiety 
disorder, panic disorder, 
obsessive-compulsive 
disorder, personality 
disorder, mental 
retardation, primary 
organic diseases, 
Diagnosis: 
Psychiatric 
evaluation 
Subtype: Not 
stated 
NR3C1 
Multiplex 
SNaPshot 
System 
Different 
types of 
SSRIs and 
SNRIs 
Dosage: Not 
stated 
8 weeks 
55% remitters 
(HAMD-17 7) 
No association between 
SNPs in NR3C1 and 
remission 
8/14 
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pregnancy, lactation, 
drugs within 2 weeks, 
electroconvulsive 
therapy within 6 months 
Takahashi, 2014 N=160 
n=94 female 
n=66 male 
Age: 50±13 years 
Ethnicity: Japanese 
Inclusion: MADRS ≥21 
Exclusion: any other 
mental disorder, severe 
medical disorder, 
psychotropic drugs 
within 2 weeks 
Diagnosis: Not 
stated 
Subtype: Not 
stated 
NR3C1 
Restriction 
fragment 
length 
polymorphism 
strategy 
Fluvoxamine 
(50mg, 
increasing to 
100mg by 
week 2, and 
200mg by 
week 3) 
Milnacipran 
(50mg, 
increasing to 
100mg by 
week 2) 
6 weeks 
65% responder 
(50% reduction 
MADRS) 
56% remitters 
(MADRS <10) 
One SNP (rs41423247) in 
NR3C1 differed between 
fluvoxamine non-
responders and responders 
No association between the 
same SNP and remission 
6/14 
Ventura-Junca, 
2014 
N=208 
n=201 female 
n=7 male 
Age: 43±11 years 
Ethnicity: Chilean 
Diagnosis: MINI 
Subtype: Not 
stated 
NR3C1 
Restriction 
fragment 
length 
polymorphism 
strategy 
Fluoxetine 
20mg/day 
(weeks 1-3), 
increasing to 
40mg/day 
(flexible, 
depending on 
tolerance) 
55% 
responders 
(50% reduction 
HAMD-17) 
39% remitters 
(HAMD-17 ≤7) 
No association between 
SNPs in NR3C1 and 
treatment response or 
remission 
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Inclusion: HAMD-17 
≥15 
Exclusion: substance 
abuse, psychotic 
disorder, bipolar 
disorder, generalised 
anxiety disorder, panic 
disorder, obsessive-
compulsive disorder, 
sever cognitive 
impairment, 
medical/neurological 
illness, acute/chronic 
infections, abnormal 
thyroid function, 
hypertension, 
pregnancy, 
breastfeeding, 
medication within 2 
months prior to study, 
history of treatment-
resistant MDD 
8 weeks 
Tiwari, 2013 N=319 
n=199 female 
n=120 male 
Age: 39±12 years 
Diagnosis: 
Investigator 
evaluation 
Subtype: Not 
stated 
NR3C1 
iPLEX 
Platform 
Bupropion 
(150-450mg) 
4-12 weeks 
60% 
responders 
(50% reduction 
HAMD-17 or 
IDS-C) 
No association between 
SNPs in NR3C1 and 
treatment response or 
remission 
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Ethnicity: African, 
European, Mexican 
Inclusion: HAMD-17 
≥17 or IDS-C ≥25 
Exclusion: alcohol or 
substance abuse, 
schizophrenia, bipolar 
disorder, panic disorder, 
obsessive-compulsive 
disorder, post-traumatic 
stress disorder, acute 
stress disorder, eating 
disorder, seizure 
disorder, brain injury, 
unstable medical 
condition, psychotropic 
drugs within 2 weeks 
42% remitters 
(HAMD-17 ≤7 
or IDS-C ≤13) 
Lee, 2009 N=96 
n=70 female 
n=26 male 
Age: 49±16 years 
Ethnicity: Korean 
Inclusion: HAMD-21 
≥17 
Diagnosis: 
SCID 
Subtype: Not 
stated 
NR3C1 
Restriction 
enzyme 
Citalopram 
(20mg, up to 
60mg 
between 
weeks 2 and 
8) 
8 weeks 
63% 
responders 
(50% reduction 
HAMD-21) 
No association between 
SNPs in NR3C1 and 
treatment response 
6/14 
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Exclusion: any other 
mental disorder, 
neurological diseases, 
chronic diseases other 
than diabetes and 
hypertension, drug 
intake within 2 weeks 
Perlis, 2009 N=250 
n=158 female 
n=92 male 
Age: 44±13 years 
Ethnicity: Caucasian 
Inclusion: HAMD-17 
≥15 
Exclusion: current 
mental disorder except 
dysthymia or anxiety 
disorders, history of 
psychosis, bipolar 
disorder, suicidal risk, 
serious medical illness, 
electroconvulsive 
therapy within 12 
months, treatment with 
MAO inhibitors within 2 
weeks, fluoxetine within 
Diagnosis: MINI 
Subtype: Not 
stated 
NR3C1 
iPlex Platform 
Duloxetine 
30-60mg 
(week 1), 
60mg (weeks 
2-6) 
6 weeks 
51% responder 
(50% reduction 
HAMD-17) 
44% remitter 
(HAMD-17 ≤7) 
No association between 
SNPs in NR3C1 and 
treatment response or 
remission 
6/14 
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4 weeks, substance 
abuse within 6 months, 
change in 
psychotherapy, 
treatment resistant 
depression, lack of 
response to duloxetine 
Uher, 2009 N=811 
n=514 female 
n=297 male 
Age: 43±12 years 
Ethnicity: European 
Inclusion: major 
depressive episode of 
at least moderate 
severity 
Exclusion: substance 
abuse, family history of 
bipolar disorder or 
schizophrenia, history 
of (hypo)manic episode, 
schizophrenia, mood 
incongruent psychotic 
symptoms, primary 
organic disease, 
pregnancy, MAO 
inhibitors or fluoxetine 
Diagnosis: 
SCAN 
Subtype: Not 
stated 
NR3C1 
SNPlex 
System 
Escitalopram 
(10mg 
increasing to 
15mg by 
week 2, with 
further 
increasing up 
to 30mg) 
Nortriptyline 
(50mg 
increasing to 
100mg by 
week 2, with 
further 
increasing up 
to 200mg) 
12 weeks 
Responder 
rate: not stated 
(50% reduction 
HAMD-17) 
No association between 
SNPs in NR3C1 and 
treatment response or 
remission 
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within 2 weeks, history 
of non-response to 
study medication 
Wong, 2008 N=230 
n=154 female 
n=76 male 
Age: 21-68 years 
Ethnicity: Mexican 
American 
Inclusion: HAMD-21 
≥18 and depressed 
mood item ≥2 
Exclusion: any other 
mental disorder except 
anxiety disorders, 
suicidal ideation, 
pregnancy, lactation, 
current use of 
medication interfering 
with electro-
encephalography, 
antidepressant intake 
within 2 weeks, drug 
use or alcohol abuse 
within 3 months, 
enrolment in 
Diagnosis: 
Unclear 
Subtype: Not 
stated 
NR3C1 
Golden Gate 
Assay 
Desipramine 
(50-200mg) 
Fluoxetine 
(10-40mg) 
8 weeks 
Responder 
rate: not stated 
(50% reduction 
HAMD-21) 
No association between 
SNPs in NR3C1 and 
treatment response 
2/14 
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psychotherapy, 
treatment resistance 
Paddock, 2007 N=935 
Sex: Not stated 
Age: 18-75 years 
Ethnicity: Black, White 
Non-Hispanic 
Inclusion: HAM-D ≥14 
and QIDS-C ≥10 
Exclusion: primary 
diagnosis of bipolar, 
psychotic, obsessive-
compulsive or eating 
disorder, pregnancy, 
breastfeeding, history of 
nonresponse to 
citalopram 
Diagnosis: 
Clinician based 
Subtype: All 
non-psychotic 
NR3C2 
BeadArray 
Platform 
Citalopram 
20mg (weeks 
1-3), 
increasing to 
40mg (week 
4) and 60mg 
(week 6) 
6 weeks 
72% 
responders 
(50% reduction 
QIDS-C), non-
responder rate: 
28% (≤40% 
reduction 
QIDS-C) 
Remitter rate: 
not stated 
(QIDS-C ≤5), 
non-remitter 
rate: not stated 
(QIDS-C ≥10) 
No association between 
SNPs in NR3C2 and 
treatment response or 
remission 
7/14 
HAMD = Hamilton Rating Scale for Depression, IDS-C = Inventory of Depressive Symptoms – Clinician-Rated, MADRS = Montgomery-Asberg Depression 
Rating Scale, MINI = Mini-International Psychiatric Interview, NR3C1 = glucocorticoid receptor, NR3C2 = mineralocorticoid receptor, QIDS-C = Quick Inventory of 
Depressive Symptomatology – Clinician-Rated, SCAN = schedules for clinical assessment in neuropsychiatry interview, SCID = Structured Clinical Interview for 
DSM, SNRI = selective noradrenaline reuptake inhibitors, SSRIs = selective serotonin reuptake inhibitors 
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Table 6 Summary of findings divided by whether they are supportive or non-supportive of a 
relationship between polymorphisms in genes related to the hypothalamic-pituitary-adrenal axis and 
response to antidepressant treatment; note that different single nucleotide polymorphisms and 
haplotypes were investigated across studies (see results section for more details) 
System Supportive Non-supportive 
Arginine 
vasopressin 
 No association between AVP and 
response or remission (Binder, 2010; 
Ventura-Junca, 2014) 
  No association between AVPR1A 
and response (Binder, 2010) or 
remission (Binder, 2010; Geng, 
2014) 
  No association between AVPR1B 
and response or remission (Binder, 
2010) 
Corticotropin-
releasing hormone 
 No association between CRH and 
response (Binder, 2010, Wong, 
2008) or remission (Binder, 2010; 
Chang, 2015a) 
 Association between CRHR1 and 
remission (Geng, 2014) 
No association between CRHR1 and 
response (Binder, 2010; Liu, 2007; 
Ventura-Junca, 2014) or remission 
(Binder, 2010; Dong, 2009; Ventura-
Junca, 2014) 
 Association between CRHR2 and 
response in treatment completers 
(Tiwari, 2013) 
No association between CRHR2 and 
response (Binder, 2010; Papiol, 
2007; Ventura-Junca, 2014) or 
remission (Binder, 2010; Geng, 
2014; Tiwari, 2013; Ventura-Junca, 
2014) 
 Association between CRHBP and 
response and remission (Binder, 
2010) 
No association between CRHBP and 
response (Wong, 2008) 
Melanocortin Association between POMC and 
remission (Chang, 2015b) 
No association between POMC and 
response (Wong, 2008) 
FK506 binding 
protein 5 
Association between FKBP5 and 
remission (Lekman, 2008) 
No association between FKBP5 and 
response (Ellsworth, 2013; Lekman, 
2008; Paddock, 2007; Papiol, 2007; 
Perlis, 2009; Tiwari, 2013; Tsai, 
2007; Uher, 2009; Ventura-Junca, 
2014) or remission (Ellsworth, 2013; 
Geng, 2014; Paddock, 2007; Papiol, 
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2007; Perlis, 2009; Tiwari, 2013; 
Tsai, 2007; Uher, 2009; Ventura-
Junca, 2014) 
Glucocorticoid and 
mineralocorticoid 
receptor 
Association between NR3C1 and 
response (Takahashi, 2014) 
No association between NR3C1 and 
response (Lee, 2009; Paddock, 
2007; Perlis, 2009; Tiwari, 2013; 
Uher, 2009; Ventura-Junca, 2014; 
Wong, 2008) or remission (Geng, 
2014; Paddock, 2007; Perlis, 2009; 
Takahashi, 2014; Tiwari, 2013; Uher, 
2009; Ventura-Junca, 2014) 
  No association between NR3C2 and 
response or remission (Paddock, 
2007) 
AVP = arginine vasopressin, AVPR = arginine vasopressin receptor, CRH = corticotropin releasing 
hormone, CRHR = corticotropin releasing hormone receptor, CRHRBP = corticotropin releasing 
hormone binding protein, FKBP = FK506 binding protein, NR3C1 = glucocorticoid receptor, NR3C2 = 
mineralocorticoid receptor, MC1R = melanocortin receptor, POMC = proopiomelanocortin 
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Supplement and Table legends 
Supplement 1 Scale to assess risk of bias in candidate-gene studies of genes related to the 
hypothalamic-pituitary-adrenal (HPA) axis and their relationship to antidepressant treatment response; 
modified from Fischer and Cleare (2017), Fischer, Macare and Cleare (2017), and Fischer et al. 
(2017) 
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